An expert, presenting at the annual meeting of the American Heart Association, said trials have shown that SGLT2 inhibitors such as dapagliflozin help improve weight, lipid profile, and blood glucose and blood pressure levels in patients with diabetes. Other research has shown that the already FDA-approved drug acarbose and insulin-based diabetes therapies also have cardiovascular benefits for patients.

Related Summaries